Etienne Suc
Clinique Saint Jean Languedoc(FR)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Prostate Cancer Treatment and Research, Lymphoma Diagnosis and Treatment, Cancer Treatment and Pharmacology, Prostate Cancer Diagnosis and Treatment
Most-Cited Works
- → Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial(2013)732 cited
- → Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.(1997)429 cited
- → Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab(2019)136 cited
- → Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model(2014)128 cited
- → Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort(2017)109 cited
- → Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia(1993)104 cited
- → Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)(2018)88 cited
- → Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)(2014)65 cited
- → Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial(2017)63 cited
- → High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.(1997)51 cited